ADXN
Income statement / Annual
Last year (2025), Addex Therapeutics Ltd's total revenue was $208.14 K,
a decrease of 48.49% from the previous year.
In 2025, Addex Therapeutics Ltd's net income was -$8.10 M.
See Addex Therapeutics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$208.14 K |
$404.10 K |
$1.61 M |
$1.42 M |
$2.92 M |
$3.61 M |
$2.76 M |
$6.04 M |
$499.89 K |
$17.33 K |
| Cost of Revenue |
$10.20 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$230.10 K
|
$144.17 K
|
$29.76 K
|
$17.33 K
|
| Gross Profit |
$197.94 K
|
$404.10 K
|
$1.61 M
|
$1.42 M
|
$2.92 M
|
$3.61 M
|
$2.53 M
|
$5.90 M
|
$470.13 K
|
$0.00
|
| Gross Profit Ratio |
0.95
|
1
|
1
|
1
|
1
|
1
|
0.92
|
0.98
|
0.94
|
0
|
| Research and Development Expenses |
$808.74 K
|
$435.19 K
|
$942.71 K
|
$7.88 M
|
$9.01 M
|
$10.37 M
|
$12.45 M
|
$2.37 M
|
$841.31 K
|
$819.33 K
|
| General & Administrative Expenses |
$0.00
|
$1.68 M
|
$2.03 M
|
$3.26 M
|
$7.75 M
|
$5.75 M
|
$4.31 M
|
$4.72 M
|
$2.20 M
|
$1.52 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.78 M
|
$1.68 M
|
$2.03 M
|
$3.26 M
|
$7.75 M
|
$5.75 M
|
$4.31 M
|
$4.72 M
|
$2.20 M
|
$1.52 M
|
| Other Expenses |
$0.00
|
$1.05 M
|
$882.25 K
|
$817.79 K
|
$1.66 M
|
-$266.32 K
|
$374.01 K
|
$382.99 K
|
$197.67 K
|
$799.70 K
|
| Operating Expenses |
$3.59 M
|
$3.16 M
|
$3.86 M
|
$11.96 M
|
$18.42 M
|
$15.86 M
|
$17.14 M
|
$7.47 M
|
$3.24 M
|
$3.14 M
|
| Cost And Expenses |
$3.60 M
|
$3.16 M
|
$3.86 M
|
$11.96 M
|
$18.42 M
|
$15.86 M
|
$17.37 M
|
$7.47 M
|
$3.24 M
|
$3.14 M
|
| Interest Income |
$0.00
|
$9.17 K
|
$63.96 K
|
$29.25 K
|
$5.32 K
|
$35.31 K
|
$36.87 K
|
$85.87 K
|
$0.00
|
$27.00
|
| Interest Expense |
$2.92 K
|
$3.55 K
|
$21.61 K
|
$48.90 K
|
$63.01 K
|
$69.50 K
|
$128.52 K
|
$220.17 K
|
$45.35 K
|
$6.92 K
|
| Depreciation & Amortization |
$10.20 K
|
$260.12 K
|
$305.95 K
|
$323.14 K
|
$347.61 K
|
$378.75 K
|
$333.84 K
|
$2.94 K
|
$15.25 K
|
$25.76 K
|
| EBITDA |
-$3.38 M |
-$4.65 M |
-$2.19 M |
-$10.45 M |
-$14.94 M |
-$12.41 M |
-$14.32 M |
-$1.51 M |
-$3.22 M |
-$3.12 M |
| EBITDA Ratio |
-16.23
|
-11.5
|
-1.36
|
-7.35
|
-5.12
|
-3.44
|
-5.18
|
-0.25
|
-6.44
|
-179.79
|
| Operating Income Ratio |
-16.28
|
-6.82
|
-1.39
|
-7.41
|
-5.32
|
-3.39
|
-5.29
|
-0.24
|
-6.47
|
-180.6
|
| Total Other Income/Expenses Net |
-$4.85 M
|
-$2.15 M
|
-$257.19 K
|
-$263.06 K
|
$154.00 K
|
-$615.33 K
|
-$176.45 K
|
-$220.17 K
|
-$45.35 K
|
-$19.79 K
|
| Income Before Tax |
-$8.24 M
|
-$4.91 M
|
-$2.50 M
|
-$10.80 M
|
-$15.35 M
|
-$12.86 M
|
-$14.78 M
|
-$1.64 M
|
-$3.28 M
|
-$3.15 M
|
| Income Before Tax Ratio |
-39.58
|
-12.15
|
-1.55
|
-7.6
|
-5.26
|
-3.56
|
-5.35
|
-0.27
|
-6.56
|
-181.74
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.92 K
|
| Net Income |
-$8.10 M
|
$7.06 M
|
-$10.56 M
|
-$20.80 M
|
-$15.35 M
|
-$12.86 M
|
-$14.78 M
|
-$1.64 M
|
-$3.28 M
|
-$3.15 M
|
| Net Income Ratio |
-38.92
|
17.46
|
-6.54
|
-14.63
|
-5.26
|
-3.56
|
-5.35
|
-0.27
|
-6.56
|
-181.74
|
| EPS |
-6.88 |
8.4 |
-16.8 |
-55.2 |
-54 |
-57.6 |
-67.2 |
-8.47 |
-30 |
-33.6 |
| EPS Diluted |
-6.88 |
8.4 |
-16.8 |
-55.2 |
-54 |
-57.6 |
-67.2 |
-8.47 |
-30 |
-33.6 |
| Weighted Average Shares Out |
$935.00 K
|
$817.61 K
|
$619.23 K
|
$376.54 K
|
$284.33 K
|
$222.35 K
|
$220.24 K
|
$194.11 K
|
$107.85 K
|
$95.10 K
|
| Weighted Average Shares Out Diluted |
$935.00 K
|
$817.61 K
|
$619.23 K
|
$376.54 K
|
$284.33 K
|
$222.35 K
|
$220.24 K
|
$194.11 K
|
$107.85 K
|
$95.10 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
